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Abstract
Background: This study aims to critically review available cost-effectiveness models for rotavirus vaccination,
compare their designs using a standardized approach and compare similarities and differences in cost-effectiveness
outcomes using a uniform set of input parameters.
Methods: We identified various models used to estimate the cost-effectiveness of rotavirus vaccination. From
these, results using a standardized dataset for four regions in the world could be obtained for three specific
applications.
Results: Despite differences in the approaches and individual constituting elements including costs, QALYs Quality
Adjusted Life Years and deaths, cost-effectiveness results of the models were quite similar. Differences between the
models on the individual components of cost-effectiveness could be related to some specific features of the
respective models. Sensitivity analysis revealed that cost-effectiveness of rotavirus vaccination is highly sensitive to
vaccine prices, rotavirus-associated mortality and discount rates, in particular that for QALYs.
Conclusions: The comparative approach followed here is helpful in understanding the various models selected and
will thus benefit (low-income) countries in designing their own cost-effectiveness analyses using new or adapted
existing models. Potential users of the models in low and middle income countries need to consider results from
existing studies and reviews. There will be a need for contextualization including the use of country specific data inputs.
However, given that the underlying biological and epidemiological mechanisms do not change between countries,
users are likely to be able to adapt existing model designs rather than developing completely new approaches. Also,
the communication established between the individual researchers involved in the three models is helpful in the
further development of these individual models. Therefore, we recommend that this kind of comparative study be
extended to other areas of vaccination and even other infectious disease interventions.
Background
Various countries are currently in the process of evalu-
ating whether or not to include rotavirus vaccination in
their national immunization programs. Two rotavirus
vaccines are currently available: Rotarix
® and Rotateq™,
marketed by GlaxoSmithKline (GSK) and Sanofi Pasteur
MSD (SPMSD), respectively. Rotavirus vaccines have
proven to be efficacious in preventing rotavirus-related
disease, gastrointestinal disease and health-care use
(general practitioner (GP) visits and hospitalizations) in
infants and toddlers [1-3].
Health-economic properties of these new vaccines
present one characteristic to be analyzed with respect to
their inclusion in National Immunization Programs
(NIPs). Numerous health-economic analyses already
exist regarding rotavirus vaccination, mostly in high-
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lyses but a few multi-country analyses [4-6]. Also, one
critical review of these existing models has already been
performed [7]. Recently, some studies have become
available targeted at situations in low- and middle-
income countries, involving all regions of the world (for
example, Vietnam, China, Kenya and Colombia [8-11]).
A review of these studies in Asia, Africa and South
America is in preparation [12]. Based on the favorable
cost-effectiveness profile of many of the models applied
in low- and middle-income countries, the World Health
Organization (WHO) advises inclusion of rotavirus vac-
cines in the NIPs [13]. However, in general, it is still not
always clear which aspects these individual models differ
on, what impact such differences have on the cost-effec-
tiveness outcomes and which model might be preferred
over the others in continental, regional or country speci-
fic situations [14].
T h i ss t u d ya i m st oc r i t i c a l l yr e v i e ws o m eo ft h e s e
available cost-effectiveness models for rotavirus vacci-
nation, compare their designs using a standardized
approach and compare similarities and differences in
cost effectiveness outcomes using a uniform set of
input parameters. WHO has initiated this study to
enable providing guidance to low- and middle-income
countries if requested, on the strengths and weaknesses
of existing health-economic models for rotavirus vacci-
nation as a basis for decisions about whether or not to
build their own models or to adapt existing models to
local situations. In particular, our study intends to help
WHO to guide individual countries on rotavirus mod-
elling, specifically national decision makers who may
have the interest, research capacity and resources to
conduct their own cost-effectiveness analyses in gener-
ating evidence for decision making on whether or not
to introduce rotavirus vaccination. Therefore, our ana-
lysis might be most suited for lower middle income
countries that have some capacity to attract global
partners for model adaptation, whereas most low
income countries may not have sufficient technical
capacity for building or ad a p t i n ge x i s t i n gm o d e l s .
Notably, our goal is neither to advocate for the use of
specific models nor to recommend individual model-
ling groups over others.
Methods
Review of models
Initially, we searched for existing health-economic mod-
els in the literature using PubMed, Embase and Web of
Science. Although the search was not limited to the
English language, the relevant papers that emerged from
the initial search and crude selection were all in English.
A further selection was made for those models to be
included in the detailed comparison based on various
criteria related to our goals of achieving diversity in
terms of provenance (public versus private), methods
(single-cohort models, multi-cohort models and so on)
and specific vaccines to be incorporated by the model
(that is, two individual vaccines exist that are slightly
different). Modelling groups were selected and con-
tacted, explicitly based on these criteria. However, avail-
ability, ease of access, complexity and time investment
of the individual research groups appeared to be the
strongest criteria in practice for inclusion in the final
comparison. In particular for those models with a high
degree of complexity, the time investment required
appeared to prevent the groups from becoming involved
in our comparison. Also, for these complex models
resource requirements for this analysis presented a
strong limitation, which could not easily be overcome
given the limited funds available by WHO for the
endeavor.
Comparative framework
As described, various cost-effectiveness models were
identified by the process described above. Their develo-
pers were contacted by a WHO officer (RH) to invite
them to participate in the model comparison. Subse-
quently, the model inclusion was co-ordinated by two
authors (RH and MP), while one author (MP) included
his own group’s model into the comparison. The pro-
cess resulted in three models provided to us, including
analyses using the standardized dataset specified below
(Table 1). From all modelling groups at least one co-
author is included in the author list of this paper. These
models represented a balanced public-private mix invol-
ving one designed by the pharmaceutical industry (Rox-
anne Rotarix™ Analyses of Economics from GSK), one
developed by public financing within a European-Union
project (POLYMOD) and one privately financed (Sanofi
Pasteur MSD) but developed by the University of Gro-
ningen within the context of an unrestricted grant
(CoRoVa Consensus Rotavirus model Vaccination).
Models included could be applied to modelling use of
either vaccine (Rotarix or RotaTeq), hence ensuring that
the unique features of the two vaccines were adequately
represented in our analysis. In addition, both manufac-
turers were directly (Roxanne) or indirectly (CoRoVa)
involved in the models. Only static models were com-
pared; this posed both a disadvantage and an advantage.
In particular, comparison with a dynamic model, which
could explicitly analyze the effect of vaccination on the
spread of rotavirus infection using mathematical model-
ling, would be extremely valuable. However, our selec-
tion of only static models for comparison enhances
comparability of the individual models and facilitates
understanding the differences that still remain between
the models’ outcomes.
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models through physical transfer of the software -
accompanied with user guides and/or publications - and
explained various concepts and characteristics of these
models face-to-face, through e-mail contacts and tele-
phone calls during 2009. Additionally, during a one-day
consultation in 2009 at the WHO headquarters in Gen-
eva, concepts and draft results were discussed with a
large group of experts in epidemiology, immunology,
vaccinology, political sciences and health economics. In
the end, final calculations were performed by the model-
lers themselves using the most current model versions
at the end of 2010 and extensively discussed during the
winter of 2010/2011. To summarize the way the three
models were included in this analysis, we note that all
the software for the models was physically available to
the coordinating team (MP and RH), at least two face-
to-face meetings between member(s) of the coordinating
team and each research group were organized and final
calculations were checked by the coordinating team and
cross-checked for face validity by all three individual
research groups.
The standardized approach in comparing these models
involved stepwise analysis of the structure, the input
parameters required and specific assumptions underly-
ing the models.
Details on available models
As mentioned, during the model selection process three
models with corresponding results for the standardized
input parameters became available to us. These were the
POLYMOD model [4,15,16], Roxanne [17-20], and CoR-
oVa [21-23].
The POLYMOD-model was developed in the context
of a European Union (EU)-funded project with the
same acronym [4]. RVGE Rotavirus GastroEnteritis was
modelled using an age-structured cohort model that fol-
lowed cohorts of vaccinated and unvaccinated indivi-
duals (Table 1). For the first year of life, the cohort was
stratified into monthly age groups, with one-year age
bands applied beyond (one to five years old). The
model was initially a single-cohort model; however, it
was adapted to a multi-cohort model for the purpose of
this exercise to allow a step-up in vaccination coverage.
RVGE was stratified into mild disease with home treat-
ment only, moderate disease with primary care visits
(GP and/or hospital outpatient), severe disease with
hospital emergency room (ER)-visits and/or admissions,
nosocomial infections andd e a t h .Q A L Yl o s s e sw e r e
incurred both by the index infants and their care givers.
QALYs were taken from one specific study on the topic
[23], which were quite comparable to those used in
some other health-economic studies [5]. The model was
designed by modellers based in England’s Health Pro-
tection Agency (HPA) with input from modellers based
in public health institutions in Belgium, Finland, France
and the Netherlands and applied to model rotavirus epi-
demiology and cost-effectiveness of vaccination in the
five countries of Belgium, England and Wales, Finland,
France and the Netherlands. Unlike most static rota-
virus models, waning vaccine immunity was explicitly
incorporated into the model structure. Further country-
specific models - based on this multi-cohort, multi-
country model - have been published, for example, for
the Netherlands [16].
Roxanne was developed as a Markov cohort process
tree [17]. It is programmed in Microsoft Excel 2007
using Visual Basic and contains both cost-effectiveness
and budget impact modules. The model was initially
parameterized with data from France [18], but allows
data from any country to be used [19]. A precursor of
the model has been used to estimate the cost-effective-
ness of Rotarix
® in the Netherlands [20]. Besides a com-
parison of vaccination versus no vaccination, the model
was designed to additionally allow explicit comparison
of two- and three-dose vaccination strategies. Obviously,
outcomes in such analyses crucially depend on the exact
characteristics and properties applied to the two- and
three-dose vaccination schedules. Finally, Roxanne
allows extensive probabilistic sensitivity analysis, using
the At Risk add-in for Excel. A special feature of Rox-
anne involves the explicit inclusion of the modelling of
Table 1 Basic characteristics of the models investigated
a
POLYMOD Roxanne CoRoVa
Developers HPA GSK University Groningen
Funding EU GSK SPMSD
Software platform Excel Excel Excel
Dynamic vs. static Static Statistic Static
Deterministic vs. stochastic Deterministic Deterministic Deterministic
Open vs. closed Open Closed Closed
Cohort vs. population-based Multi-cohort Cohort Cohort
Special features Stepwise waning Breastfeeding effects modeled In- between dose efficacies modeled
aSpecific questions regarding the three models should be attended to Dr Raymond Hutubessy (email address: hutubessyr@who.int)
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breastfeeding.
CoRoVa was initially developed for the specific Dutch
situation and aimed at achieving consensus among var-
ious Dutch modelling groups that had previously
worked on the cost-effectiveness of rotavirus vaccination
[16,20]. An age-structured cohort model was developed
in Excel applying a time horizon of five years with time
cycles of one month for children less than one year of
age and annual thereafter [21-23]. Outcomes in the
model were classified by severity and included home-
treated community-acquired diarrhea and rotavirus
infection leading to GP consultations and/or hospital
admissions (including emergency department visits),
nosocomial infections and death. Specific characteristics
o ft h em o d e la r et h ea b i l i t yt ot a k ew a n i n gi m m u n i t y ,
maternal protection against infection through breast-
feeding, and herd protection into account. However, the
model is not a transmission dynamic model because
herd protection is incorporated by straightforward cal-
culus only, using a static approximation based on a
fixed fraction of the direct effects. In the base-case ana-
lysis for the Netherlands, QALY losses of caregivers
were not included and the QALY decrement for chil-
dren was based on a combination of two published stu-
dies performed in Canada and the United Kingdom
[24,25]. Similar to the Roxanne-model CoRoVa also
used the At Risk software for (probabilistic) sensitivity
analyses.
Standardized input parameters
For this study, analyses of the models were provided
regarding their structure and outcomes for four
hypothetical countries, representative of different conti-
nents and income levels (low, middle or high), respec-
tively classified into the WHO geographical regions and
mortality strata [14]. In particular, sets of standardized
input parameters were provided to the modellers and
analyzed for a hypothetical Afr E country representing
the African region with high child and very high infant
mortality; a hypothetical Sear D country representing
the South-east Asian region with high child and adult
mortality; a hypothetical Amr D country representing
the South and Middle American regions with again high
child and adult mortality; and a hypothetical Eur A
country representing developed countries in the Eur-
opean setting. Tables 2, 3, 4 and 5 summarize the set of
standardized input parameters. Rectangular age distribu-
tions were assumed, implying that life expectancy
decreases with one year exactly for every one-year
increase in the age of infants and toddlers considered.
(For example, if life expectancy is 70 at birth, it would
be 69 at the age of 1, 68 at the age of 2 and so on). Sim-
plifying assumptions were justified as our interest con-
cerned the comparison between models rather than the
exact representation of country-specific demographic,
epidemiological and economic impacts.
Although the time horizon in the single- and multi-
cohort models was lifetime, this effectively produced a
time horizon of five years after the birth of the last
cohort, since it is assumed that no rotavirus gastroenter-
itis occurs beyond the age of five years and vaccination
is only investigated in infants in their first year of life.
Various sources were utilized for parameter estimates as
indicated in Tables 2, 3, 4 and 5[1-5,7,14,15,20,26-31].
However, as the objective was comparative rather than
Table 2 Standardized dataset for the cost-effectiveness models in rotavirus vaccination: demography and incidence
(Sources: [4,5,7,14,15,20,26,27])
Afr Sear Amr Eur Notes
Total # of life births 1,496,200 3,427,800 140,110 190,000
Life expectancy at birth in years 54 66 73 80 average men & women
Population 34,255,722 141,822,276 5,486,685 16,500,000
% of population < 5 years 16.8% 16.8% 16.8% 6.1%
% urban 42% 23% 62% 100%
Infant mortality (< 1 year of age) 64 45 21 4 per 1000 life births
Mortality < 5 years 104 57 26 0.5 per 1000 life births/yr
Population < 5 years 5,736,373 17,399,197 730,913 1,000,000
Incidence mild rotavirus gastro-enteritis
1st year after birth 1.4% 1.4% 1.4% 1.4% in % per month
2nd year after birth 0.57% 0.57% 0.57% 0.57% in % per month
3rd & 4th after birth 0.49% 0.49% 0.49% 0.49% in % per month
Incidence of moderate 38.7% 38.7% 38.7% 33.1% in % from mild
Incidence of severe 7.9% 7.9% 7.9% 12.1% in % from moderate
Incidence of death 18.8% 12.5% 6.3% 0.05% in % from severe
Incidence of nosocomial infections 33.3% 33.3% 33.3% 25% % from severe (on top)
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Page 4 of 11to exactly mimic the situations of specific countries
often plausible assumptions were made rather than
exact replications of individual sources. Plausibility of
assumptions was primarily based on the expert opinions
of two of the authors (MP and MJ).
Key parameters for all analyses were the incidence of
rotavirus gastroenteritis (RVGE), the corresponding risks
of rotavirus-related health-care use, as well as corre-
sponding costs. All cases with RVGE were assumed to
be treated at home. In particular, moderate cases were
assumed to involve one additional outpatient visit (GP,
health center or hospital) and severe cases were
assumed to involve: home treatment, an outpatient visit
and a hospitalization. Some models had the additional
option of severe cases not being hospitalized. Based on
data from the clinical trials, vaccine efficacy could be
specified for different outcomes and for high-income
versus other countries.
Alternatively to what is expressed in Table 1, inci-
dence could be expressed as average annual risks over
the same five years considered in the data and model-
ling. In particular, the average annual risks at population
level are 10,440, 4,040 and 320 per 100,000 people in all
developing regions for mild, moderate and severe,
Table 3 Standardized dataset for the cost-effectiveness models in rotavirus vaccination: vaccine characteristics
(Sources: [1-5,7,15,20,28], expert opinions)
Afr Sear Amr Eur Notes
Efficacy, assuming a 2-dose schedule at 2 & 3 months
(1 dose only between brackets)
Mild 52% (52%) 52% (52%) 52% (52%) 87% (87%)
Moderate 55% (54%) 55% (54%) 55% (54%) 92% (90%)
Severe 60% (54%) 60% (54%) 60% (54%) 100% (90%)
Waning of efficacy (annual)
Mild & moderate 0.63 0.63 0.63 0.63 multiply each next year
Severe 0.83 0.83 0.83 0.83 multiply each next year
Coverage
Dose 1 50% 50% 50% 50%
Dose 2 40% 40% 40% 40%
20 years after introduction 80% 80% 80% 96% for both doses
Coverage improvement linear linear linear linear
Per-dose vaccine costs (2 doses)
2009-2014 7.5 7.5 7.5 45
2015 & beyond 4444 5
Table 4 Standardized dataset for the cost-effectiveness models in rotavirus vaccination: health-care use and costs
Afr Sear Amr Eur Notes
Average length of hospital stay 4 4 4 4 days
Cost per hospital day US$35 US$34 US$122 € 550
Cost per outpatient visit (health center/GP) US$10.50 US$9 US$34.50 € 40 Community acquired only
Out-of-pocket costs (comm.-acq. only) US$0.50 US$2.5 US$5 € 15 diapers/travel/OTC
Total direct costs for nosocomial cases US$15 US$15 US$50 € 2,000
Cost of productivity loss/day US$1 US$5 US$10 € 125
Parents with work loss
Non-hospitalized 20% 20% 20% 20%
Hospitalized & nosocomial 75% 75% 75% 75%
Days of work missed for parents
Mild 1 1 1 1
Moderate 1.5 1.5 1.5 1.5
Severe 2 2 2 2 also for nosocomial
Discount rates 3% 3% 3% 3% money & health
Administration costs per dose US$0.53 US$0.46 US$0.46 € 5
(Note: all mild cases were treated at home, all moderate additionally in an outpatient setting, such as outpatient hospital, general practitioner or health center
and all severe cases additionally in hospital; all cases have out-of-pocket costs), plausible assumptions based on literature [29-31] and expert opinions (MP & MJ))
GP: general practitioner; comm.-acq: community acquired; OTC: over the counter
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are 10,440; 3,460; and 419 per 100,000 people. Similarly,
annual mortality risks are 60, 40, 20 and 0.21 per
100,000 population for the Afr, Sear, Amr and Eur
regions, respectively.
Standardized output
Model developers were requested to present a standar-
dized set of output variables for one single cohort (for
the multi-cohort model, the coordinating center esti-
mated the results for one cohort themselves). In particu-
lar, these were: total number of persons and (person-
years if available) followed in the model; undiscounted
number of mild cases of RVGE; undiscounted number
of moderate cases of RVGE; undiscounted number of
severe cases of RVGE; undiscounted number of outpati-
ent visits (GP, outpatient or health center; typically this
would equal the number of moderate and severe cases);
undiscounted number of hospitalizations (typically equal
to the number of severe cases); undiscounted number of
nosocomial cases (equal to 1/4 or 1/3 of the number of
hospitalizations, in the Eur and other regions, respec-
tively); undiscounted number of deaths; discounted
direct outpatient costs; discounted direct inpatient costs;
discounted vaccination costs; discounted and undis-
counted QALYs due to deaths (difference between vac-
cination and no vaccination is equal to the number of
life-years gained); discounted and undiscounted QALYs
due to morbidity; cost/QALY from the health-care per-
spective; cost/QALY from the societal perspective; and
finally, a sensitivity analysis was requested by varying
parameters values through halving and doubling their
base case values, except the discount rate which was
investigated for alternative values of 0% and 4%.
In particular, cost-effectiveness was expressed in net
costs per QALY gained by subtracting discounted sav-
ings from the reduced need for RVGE treatments from
(discounted in the multi-cohort model) vaccination
costs to provide the numerator and dividing by the
QALYs gained (the denominator).
Results
Results of using the standardized dataset for the various
regions in different models are shown in Tables 6, 7, 8,
9 and 10 for all three models. In general, cost-effective-
ness results are broadly similar and comparable.
However, there are differences in the building blocks
of these cost-effectiveness ratios, for example, regarding
estimations of QALY losses related to morbidity in the
three models. The results for the CoRoVa model were
g e n e r a l l yi nb e t w e e nt h o s ef o rt h eo t h e rt w o .T h eR o x -
anne model generally predicts an overall higher number
of cases, most notably for hospitalized cases. This trans-
lates into relatively high inpatient savings that are how-
ever lowered by discounting and overall dominated by
vaccination costs to render similar net discounted costs
for all three models investigated. However, the POLY-
MOD model gave consistently lower results for these
discounted net costs; this might be due to the approxi-
mation from results for the multiple cohorts to just one.
Table 5 Utility losses and some remaining issues [4,5,7,20,27]
Afr Sear Amr Eur Notes
Disutility
Mild 0.15 0.15 0.15 0.15 during 4 days
Moderate 0.25 0.25 0.25 0.25 during 8 days
Severe 0.7 0.7 0.7 0.7 during 11
days
Nosocomial 0.7 0.7 0.7 0.7 during 4 days
Death 1111p e r year
Age weighting (primarily considered for
DALYs)
off off off off
Perspective societal & health
care
societal & health
care
societal & health
care
societal & health
care
Herd effect off off off off
DALY: disability adjusted life year
Table 6 Comparative analysis on costs per QALY
POLYMOD Roxanne CoRoVa
Health-care perspective
Afr $ 265a $ 188-367
b $ 233-440
b
Sear $ 358a $ 257-503
b $ 308-591
b
Amr $ 307a $ 200-652
b $ 336-862
b
Eur € 57,897 € 50,999 € 56,656
Societal perspective
Afr $ 260a $ 185-364
b $ 231-438
b
Sear $ 328a $ 241-487
b $ 293-577
b
Amr $ 196a $ 143-595
b $ 282-809
b
Eur € 49,427 € 40,041 € 44,263
a. based on future reduction of vaccine prices from $7.5 to $4; b. Range given
for previous upper and lower vaccine prices
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cohort model were offset by a higher number of cases
averted in the single-cohort model, resulting in the com-
parable cost-effectiveness ratios between the two types
of models. Results suggest that rotavirus vaccination
could potentially be cost-effective in all regions, particu-
larly in low and middle income countries. However, the
standardized data set is highly generalized and not spe-
cific to any individual country, so conclusions to support
policy making should not be drawn in the absence of
country-specific analyses.
Figure 1 shows the sensitivity analysis performed on
the model results, with the example of CoRoVa shown
here (other models showed similar patterns). From pre-
vious work on cost-effectiveness of rotavirus vaccination
[5,7,15,19], it is well-known that generally these results
Table 7 Outcomes predicted by models for one birth
cohort in Afr-region
POLYMOD
a Roxanne CoRoVa
Undiscounted cases
Mild 92,989 121,312 128,807
Moderate 49,051 70,126 54,559
Severe 5,092 9,589 5,277
Nosocomial 1,680 1,986 2,701
Deaths 955 1,789 1,524
Outpatient 54,143 70,126 54,559
Inpatient (comm. acq.) 5,092 9,589 5,277
Discounted savings
Outpatient $568,502 $716,305 $623,977
Inpatient $973,247 $1,329,538 $753,884
Indirect $108,916 $106,377 $81,486
Discounted net costs
b
(*1000)
$6,759 $ 8,757-
17,094
$ 9,250-
17,467
Discounted QALYs
Mortality 24,962 45,817 39,070
Morbidity 542 762 628
a. Approximation for one cohort from the multi-cohort results; b. Health-care
perspective and range given for previous upper and lower vaccine prices if
appropriate.
Table 8 Outcomes predicted by models for one birth
cohort in Sear-region
POLYMOD
a Roxanne CoRoVa
Undiscounted cases
Mild 216,205 276,861 299,907
Moderate 114,255 159,129 127,020
Severe 11,887 22,086 12,325
Nosocomial 3,923 4,748 6,309
Deaths 1,486 2,752 2,366
Outpatient 126,142 159,129 127,020
Inpatient (comm. acq.) 11,887 22,086 12,325
Discounted savings
Outpatient $1,135,274 $1,391,130 $1,852,744
Inpatient $2,208,959 $2,975,397 $1,712,409
Indirect $1,267,227 $1,213,598 $948,564
Discounted net costs
b
(*1000)
$15,424 $ 19,969-
39,083
$ 20,545-
39,423
Discounted QALYs
Mortality 41,822 75,969 65,244
Morbidity 1,261 1,731 1,462
a. Approximations for one cohort from the multi-cohort results; b. Health-care
perspective and range given for previous upper and lower vaccine prices if
appropriate.
Table 9 Outcomes predicted by models for one birth
cohort in Amr- region
POLYMOD
a Roxanne CoRoVa
Undiscounted cases
Mild 8,989 11,318 12,481
Moderate 4,760 6,471 5,286
Severe 496 897 514
Nosocomial 164 193 263
Deaths 31 59 50
Outpatient 5,256 6,471 5,286
Inpatient (comm. acq.) 496 897 514
Discounted savings
Outpatient $181,333 $216,626 $239,534
Inpatient $330,083 $432,618 $255,186
Indirect $105,467 $98,697 $78,947
Discounted net costs
b (*1000) $293 $ 346-1,127 $ 495-1271
Discounted QALYs
Mortality 900 1,662 1,413
Morbidity 53 66 61
a. Approximations for one cohort from the multi-cohort results; b. Health-care
perspective and range given for previous upper and lower vaccine prices if
appropriate
Table 10 Outcomes predicted by models for one birth
cohort in Eur-region
POLYMOD
a Roxanne CoRoVa
Undiscounted cases
Mild 22,708 32,186 28,680
Moderate 10,360 14,580 10,430
Severe 1,658 2,324 1,806
Nosocomial 415 528 452
Deaths 1 1 1
GP-visits 12,019 14,580 10,430
Inpatient (comm. acq.) 1,658 2,324 1,860
Discounted savings
Outpatient €480,745 €556,984 €829,111
Inpatient €4,643,286 €5,949,119 €4,714,920
Indirect € 1,322,021 € 2,111,857 € 2,088,993
Discounted net costs
b € 9,032,932 € 9,842,807 € 9,518,208
Discounted QALYs
Mortality 25 27 26
Morbidity 131 166 142
a. Approximations for one cohort from the multi-cohort results; b. Health-care
perspective.
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ciated mortality and the discount rate. Our analysis
shows a similar pattern for all regions investigated.
However, there is an interest i n gs h i f to b s e r v e di nv a r i -
ables influencing the cost-effectiveness results between
EU and non-EU countries. In the EU region the inci-
dence of the disease is a driver followed by utility
weights whereas in the non-EU region mortality is
essentially driving the result.
Discussion
We identified various models used to estimate the cost-
effectiveness of rotavirus vaccination. From these, results
using the standardized dataset could be obtained for
three specific applications (the POLYMOD, Roxanne
and CoRoVa models). Despite differences in the
approaches, cost-effectiveness results of the models were
quite similar. Differences between the outcomes of the
specific building blocks of the cost-effectiveness (that is,
vaccination costs, savings and QALYs gained) of the
models currently investigated seem to relate to five
aspects of the models: the multi-cohort nature of the
POLYMOD model which assumed a step up in vaccina-
tion coverage (and hence in vaccination costs as well as
cases prevented); the exact timing of the waning in the
models and in particular the exact modulation of
between-dose efficacies in the CoRoVa model; assump-
tions about the distribution of cases of different severity
levels within the one-year age groups provided (for
example, assuming a Weibull distribution in the Rox-
anne model); and the possibility in the models of experi-
encing subsequent episodes of rotavirus infections and/
or experiencing episodes with multiple manifestations
(for example, first moderate progressing to severe) and
types of health-care use (for example, inpatient and out-
patient, rather than just one of both).
Ergo, differences between the models on the individual
components of cost-effectiveness could be related to
some specific generic features of the models with
regards to representing vaccine uptake and pricing,
within age-group distributions, waning and between-
dose efficacies and inclusion of additional groups and
episodes in the general design of these models. Sensitiv-
ity analysis revealed that cost-effectiveness of rotavirus
vaccination is highly sensitive to vaccine prices, rota-
virus-associated mortality and discount rates, in particu-
lar that for effects. This is fully in line with other
authors’ findings [32].
A B
C
D
€100 €300 €500 €700 €900
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Incidenceofmortality
Discountrate
IncidenceofRVGE
Directandindirectcosts
Utilityweights
€200 €400 €600 €800 €1,000
Vaccineprice
Incidenceofmortality
Discountrate
IncidenceofRVGE
Directandindirectcosts
Utilityweights
€0 €500 €1,000 €1,500 €2,000
Vaccineprice
Incidenceofmortality
Discountrate
IncidenceofRVGE
Directandindirectcosts
Utilityweights
€0 €25 €50 €75 €100 €125
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Figure 1 Sensitivity analyses on the base case cost effectiveness ratio ($ per QALY, except in D where €‘ s *1000 were used) using the
CoRoVa model for Afr (A), Sear (B), Amr (D), and Eur (D) regions. Parameters were varied through halving and doubling, except for the
discount rates which were 0% and 4% for both costs and health effects. Dark bars show the incremental cost effectiveness ratio after a 100%
decrease in the parameter, whereas light bars show the incremental cost effectiveness ratio after a 100% increase (note that an increase in the
incidence or the costs resulted in negative cost effectiveness ratios in the Eur region [D]). Note that when the incidence of RVGE was increased
or decreased, the total number of deaths was kept constant to identify the sole effect of incidence. QALY, quality adjusted life year; RVGE,
rotavirus gastroenteritis.
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Page 8 of 11Unfortunately, we were not able to include a model
with a transmission dynamic approach in our model
comparison, instead of the cohort approach followed in
the three models analyzed. Emerging evidence that herd
immunity effects might be relevant for rotavirus trans-
mission and vaccination enhances the relevance of con-
sidering populations and transmissions between cohorts
[33-35]. Inability to include these models was often
related to the complexity of these models and the diffi-
culties to adequately grasp these complexities in the
standardized framework provided on inputs and outputs.
However, for further work it is important to also analyze
such dynamic models given their major advantage of
incorporating infection dynamics including herd immu-
nity effects and potential age shifts in epidemiology [36].
Also, differences in uptake between high-, middle-, and
low-income countries should be analyzed using dynamic
models given the different impacts of coverage levels on
herd immunity.
The three models selected for our analysis were all
basically developed for high-income countries. For rea-
sons stated previously, other models - inclusive of mod-
els developed initially for low- and middle-income
settings - could unfortunately not be considered in our
comparison. As one consequence, all the publications
arising from these models involved costs per QALY
gained rather than costs per DALY Disability Adjusted
Life Year averted. Although not undisputed, for low-
and middle-income settings DALYs rather than QALYs
a r et h ec o m m o nm e t r i cu s e d[ 2 7 , 3 7 ] .W ed on o t et h a t
one specific study showed that results differ only slightly
if DALYs are used instead of QALYs; in particular, it
showed slightly more favorable cost-effectiveness for
D A L Y sa st h eo u t c o m e[ 1 6 ] .H o w e v e r ,i th a sb e e n
demonstrated that the decision about whether or not to
include caregiver QALYs has a major impact on results
[4,7]. The appropriateness of including QALYs beyond
the index case of disease is being debated; it could be
argued that caregivers’ QALYs are particularly important
for rotavirus as they can be measured directly, and
hence may be more valid than QALYs in small children
with RVGE, where proxy measurements have to be used
[7,21,22].
Our findings for the regions Afr, Sear, Amr and Eur
should not be considered as exact representative results
and policy making should not directly be based on this.
For example, it is very unlikely that the similarities
assumed for the proportion of RVGE cases that are
mild, moderate and severe are valid in real world. This
simplifying assumption was made in order to test the
models generically and consistently. Nevertheless, our
results clearly indicate a general trend of increasingly
more favorable cost-effectiveness when going from high-
to middle- and on to low-income countries, respectively.
As the sensitivity analysis shows, this is obviously pri-
marily related to vaccine pricing and the QALY-impact
of averted mortality due to rotavirus infection. However
for actual policy making, countries will need to either
f u r t h e rc o n s i d e rt h er e s u l t sf r o me x i s t i n gs t u d i e sa n d
reviews, or initiate country-specific cost-effectiveness
analyses. For countries that have the capacity and
resources to model the cost-effectiveness of rotavirus
vaccine, our comparative analysis can help inform the
design of new models or selection of existing models to
support national-level decision making.
Hence, although our analysis is not meant to directly
inform policy making, it offers considerable guidance for
design and/or selection of a model for adaptation to
individual (low-income) countries that want to conduct
cost-effectiveness analyses. Scarce resources in these
countries may direct the choice towards adapting an
existing model rather than initiating the development of
a new approach. Reassuringly, our analysis suggests that
different models produce similar cost-effectiveness esti-
mates, illustrating that the exact choice of which model
to adapt may not be as crucial as the choice of assump-
tions and parameter values to incorporate in the model.
Conclusions
We conclude that our approach is helpful on two speci-
fic levels. Firstly, the comparative approach followed
here is helpful in understanding the various models
selected and will thus benefit (low-income) countries in
designing their own cost-effectiveness analyses using
new or adapted existing models. Secondly, we find that
the communication between the individual researchers
involved in the three models was helpful in the further
development of these individual models and will be so
in the future. Therefore, we recommend that this kind
of comparative study be extended to other areas of vac-
cination and even other infectious disease interventions,
beyond the three areas that have been explored by
WHO (pneumococcal vaccination, human papilloma
virus vaccines and (here) rotavirus) [38-40].
Finally, the models reviewed in the exercise gave simi-
lar and comparable results which appear to have face
validity. Hence it appears possible to recommend their
use in policy settings, at least for high income countries.
However, potential users of the models need to consider
the specific building blocks of the cost-effectiveness
models including the nature, scope, design and assump-
tions made and how they affect outcomes. Potential
users of the models in low and middle income countries
need to consider results from existing studies and
reviews. There will be a need for contextualization
including the use of country specific data inputs. How-
ever, given that the underlying biological and epidemio-
logical mechanisms do not change between countries,
Postma et al. BMC Medicine 2011, 9:84
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Page 9 of 11users are likely to be able to adapt existing model
designs rather than developing completely new
approaches. Also, transmission dynamic effects are likely
to be important, particularly when considering the effect
of vaccination (since vaccination can affect other cohorts
besides those vaccinated). Hence, we would recommend
that future cost-effectiveness tool comparison exercises
include dynamic models.
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